Pear Therapeutics Adds Two PDTs To Treat Depression
Pear Therapeutics acquired a digital therapeutic for depression from Waypoint Health and licensed an Internet-based cognitive behavior therapy program for residual symptoms of depression from a psychologist in Sweden.
You may also be interested in...
Availability of Spanish-language prescription digital therapeutics for the treatment of substance use disorder and opioid use disorder will address important health equity and health care disparities, according to Pear.
Medtech Insight spoke to Pear Therapeutics CEO Corey McMann about the emerging digital therapeutics market and his company’s future now that it has the first PDT covered by Medicaid.
Experts foresee the digital therapeutics market growing to $6bn-$9bn by 2025, driven in part by tech-empowered consumers and patients looking for solutions to better manage their own health and conditions. For medtechs, collaborations with software-driven start-ups will be key to harnessing personalized data and differentiating themselves in the marketplace.